Bausch Health has acquired an exclusive license for Clearside Biomedical’s Xipere, according to a press release.
Xipere (triamcinolone acetonide suprachoroidal injectable suspension) is designed to be administered using Clearside’s proprietary SCS microinjector for the treatment of macular edema associated with uveitis.
Under the terms of the licensing agreement, Bausch Health will pay up to $20 million to Clearside before launch, including an upfront payment upon signing, as well as additional payments based on sales-based milestones and regulatory approvals for additional
Uncategorized